 InPharm |
Pfizer accelerates Crizotinib regulatory procedures
Pharmaceutical Business Review Pfizer has received the US Food and Drug Adminstration's (FDA) acceptance for filing new drug application (NDA) for Crizotinib as a treatment for the patients who are suffering from ALK-positive advanced non-small cell lung cancer (NSCLC). … Pfizer Lung Cancer Drug to Get Priority Review FDA Grants Pfizer Priority Review For Lung Cancer Drug Pfizer lung cancer drug – Is FDA becoming more Open to Experimental Therapies? |
View full post on lung cancer – Google News
